2025年前三个季度,国产创新药的对外授权交易表现抢眼,二级市场多家创新药企业股价持续走强。无论是License-out、NewCo,还是近期兴起的co-co合作形式,均成为医疗行业从业者与投资者热议的焦点。近日,荃信生物发布公告,与罗氏制药达成全球独家合作与许可协议,罗氏将获得荃信生物自主研发的长效自免双抗QX031N的全球开发、注册、生产及商业化权益。协议含7500万美元首付款、最高9.95...
Source Link2025年前三个季度,国产创新药的对外授权交易表现抢眼,二级市场多家创新药企业股价持续走强。无论是License-out、NewCo,还是近期兴起的co-co合作形式,均成为医疗行业从业者与投资者热议的焦点。近日,荃信生物发布公告,与罗氏制药达成全球独家合作与许可协议,罗氏将获得荃信生物自主研发的长效自免双抗QX031N的全球开发、注册、生产及商业化权益。协议含7500万美元首付款、最高9.95...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.